The usage of anti-PrP antibodies represent one of the most promising strategy for the treatment of prion diseases. In the present study, we screened various anti-PrP antibodies, with the aim to identify those that will block PrP Sc replication in prion infected cell culture. 
SUMMARY
The usage of anti-PrP antibodies represent one of the most promising strategy for the treatment of prion diseases. In the present study, we screened various anti-PrP antibodies, with the aim to identify those that will block PrP Sc replication in prion infected cell culture.
Two antibodies, SAF34 recognizing the flexible octarepeats region on HuPrP protein and SAF61 directed against PrP amino acid residues (144-152), not only inhibited PrP Sc formation in prion-infected neuroblastoma cells but also decreased the PrP C levels in non infected N2a cells. In addition, treatment with both SAF34 and SAF61 antibodies decreased the PrP C and the PrP Sc levels in the cells, synergistically. In presence of both antibodies, our results showed that the mode of action which leads to the disappearance of the PrP Sc in cells is directly coupled to PrP C degradation by reducing the half-life of the PrP C protein.
INTRODUCTION
The prion agent lies at the heart of several fatal neurodegenerative diseases including
Creutzfeldt-Jakob disease (CJD) in humans and Transmissible Spongiform Encephalopathies (TSE) in animals (Prusiner et al. 1998) . The understanding of the molecular basis for prion diseases, such as the replication cycle of the infectious agent still remains unclear (Telling et al. 1996) . A common feature in prion diseases is the accumulation of an abnormal isoform (PrP Sc ) of a host-encoded prion protein (PrP C ) in the central nervous system. The differences in structure between the two isoforms, PrP C and PrP Sc , are well characterized. Monomers as well as dimers of the recombinant PrPP C exhibited a structure rich in α-helices (Riek et al. 1996; Donne et al. 1997; Knaus et al. 2001) . By contrast, electron microscopy analysis of 2D crystals of purified hamster PrP Sc confirmed the increasing content in β-sheets present in the abnormal isoform and revealed a structure organized in parallel β-helices (Caughey et al. 1991; Pan et al. 1993; Wille et al. 2002) . Differences in biochemical properties between these two isoforms allows for their discrimination. For instance, PrP Sc is resistant to partial digestion by proteinase-K whereas PrP C is completely hydrolyzed (Meyer et al. 1986 ).
Concerns about prion disorders have been heightened by the appearance of the bovine spongiform encephalopathy (BSE) in Great Britain and in many herds from other european countries. In addition, 137 cases of young adults have developed new variant CreutzfeldtJakob disease (vCJD) after exposure to bovine prions, most likely through consumption of contaminated-beef product . Although the total number of new vCJD cases seems to not follow the initial prediction by Ghani et al. (1998) , we can not exclude an augmentation of cases in the future (Ghani et al. 1998) . Currently, no effective therapy exists and the development of novel therapeutic strategies against prion diseases has become a priority.
New chemical molecules discovered serendipitously like branched polyamines (Supattapone et al. 1999) , phtalocyanines, porphyrins (Caughey et al. 1998) , quinacrine and chlorpromazine (Korth et al. 2001 ) demonstrated their ability to cure the scrapie-infected neuroblastoma cells (ScN2a) from their PrP Sc molecules and have been shown to diminish the infectious titer in mice. Quinacrine and chlorpromazine, well known for the treatment of malaria and various psychoses, are currently administered to patients suffering from sporadic CJD or vCJD. It remains to be determined if the drug quinacrine will prove effective in treating prion diseases in humans as it is not efficient in mice (Collins et al. 2002; Barret et al. 2003) . Porphyrins gave the most interesting results in vivo and increased the survival time up to 165 % in mice depending of the protocol of administration, which suggests that this drug might be used as a post-exposure prophylactic treatment (Priola et al. 2000) .
In parallel, rational drug design strategies, which are the basis of most modern drug discoveries, are difficult to set up for prion diseases (Perrier et al. 2000) . Until recently, this was due to the absence of a well-defined tertiary and/or quaternary structure for both PrPP Sc and PrP C isoforms, as well as a lack of knowledge of the replication cycle of the prion agent.
Only antibodies directed against the prion protein can abrogate these barriers and might, therefore, represent the most promising therapeutic strategy for the treatment of prion diseases (White et al. 2003) . Anti-PrP antibodies bind their target with a high affinity and seem to inhibit the replication cycle of the prion agent by disrupting the interaction between PrP C P and PrP Sc molecules (Enari et al. 2001; Peretz et al. 2001 ). In addition, scrapie pathogenesis is prevented in transgenic mice expressing anti-PrP antibody fragments, sustaining the development of a vaccination strategy (Heppner et al. 2001) . Alternatively, by stimulating the Perrier, 15th December 2003 innate immunity of mice with small CpG deoxyoligonucleotides, Sethi et al., succeeded to delay prion disease symptoms (Sethi et al. 2002) .
In the present study, we identified two antibodies, SAF34 and SAF61, that not only inhibited BioWhittaker. Secondary antibodies were from Jackson ImmunoResearch (West Grove, PA).
All other chemicals were from Sigma. Monoclonal antibodies SAF32, SAF34, SAF37, SAF60, SAF61, SAF69 and SAF70 were generated in the laboratory of Jacques Grassi (Demart et al. 1999) . Scrapie-associated fibrills from infected hamster brains were inoculated to knock-out Prnp 0/0 mice, as immunogen by using conventional procedures. These monoclonal antibodies were proved to recognize continuous epitopes as seen by checking their reactivity with PrP synthetic peptides, using enzyme immunoassay measurements (Demart et al. 1999 ) (see Table 1 for epitope mapping). Monoclonal antibodies 3B5 and 11C6
were produced against human recombinant PrP and were kindly provided by Dr. Krasemann (Krasemann et al. 1996a; Krasemann et al. 1996b ). mAb to Glyceraldehyde-3-PDH was commercialized by Biodesign Int.
with 10 % Fetal Calf Serum, 1% penicillin-streptomycin and 300 µg/ml geneticin. Cells were maintained at 37°C with 5% CO 2 .
Screening procedure of the antibodies. N2a58/22L cells seeded in 6-well plates (5.10 5 cells/well) containing 3 ml of supplemented MEM medium, were incubated with 10 µg/ml of non-purified antibodies (ascitis) over 3 days. Cell lysates were prepared as previously described (Perrier et al. 2000) . The protein concentration of each sample was measured with the BCA reagent (Pierce). Samples of equal protein amounts and volumes were digested with 20 µg/ml of proteinase K at a ratio of 1:50 (protease to protein) for 1h at 37°C. Digestion were stopped by 1 mM Pefabloc and the samples were centrifuged at 20 000 g, for 30 min at 4°C. Pellets were resuspended in 40 µl of SDS Denaturation buffer, and boiled 3 min before loading them on 12 % SDS-PAGE precast Criterion gel (Biorad).
Western blotting of separated proteins was performed by standard procedures. The MoPrP was detected by using a mixture of three monoclonal antibodies SAF60, SAF69 and SAF70, termed SAFmix, as previously described (Nishida et al. 2000) . 
Dose-dependent inhibition of PrP

Time course inhibition assay in normal N2a58 and prion-infected N2a58/22L cell lines.
Identically seeded cells (about 10 6 cells in 25-cm 2 flasks) were incubated with 1 µg/ml of purified monoclonal antibodies either SAF34 or SAF61 or both of them. After 3 days, confluent cells were serially split in duplicate flasks, one flask used for western blot analysis and the other one for the prolongation of the treatment with the antibody. The treatment was performed for an extended period of time, up to 20 days. Every 3 days, cell lysates from N2a58/22L were collected and analyzed according to the protocol described above. Cellular extracts were also probed with Mab Glyceraldehyde-3-PDH at 0.5 µg/ml before proteinase K digestion, to check if the protein content was equivalent between each samples. anti-PrP antibodies on PrP C half-life, cells were pulse-labeled (300 µCi/dish) for 1 hour and rinsed with MEM medium. During the chase, 2 µg/ml of SAF34 or SAF61 antibodies, or both of them at 2 µg/ml each, were added to the cells for a period of 1h, 3h and 5h. To analyze the effect of anti-PrP antibodies on PrP C synthesis, cells were pulse-labeled (300 µCi/dish) for 30 min and no chase was done. Then, cells were rinsed 3 times with 1 ml of cold PBS and lyzed by addition of 600 µl of lysis buffer (supplemented with 0.5% SDS). Samples were boiled 10 min at 95°C before immunoprecipitation of the PrP C . 200 µl of sample were diluted with 800 µl of buffer (0.5% Triton X-100, 50 mM TrisHCl pH 7.5, anti-proteases cocktail) before their incubation with 5 µl of purified SAF61 antibodies overnight at 4°C. Protein A sepharose beads were added for 2h at 4°C. The immuno-adsorbed proteins were washed 3 times in RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM TrisHCl pH 7.5) and beads were resuspended in Laemmli buffer, then boiled for 10 min at 95°C. After centrifugation, immunoprecipitated proteins were collected in the supernatant and loaded on 12.5% SDS-PAGE gel, followed by autoradiography.
Metabolic labeling and Immunoprecipitation of PrP C in N2a58 cells
mRNA analysis by RT-PCR
Total RNA was extracted from antibody treated N2a58 cells (10 6 cells) using the SV Total RNA Isolation System (Promega). Then mRNA was isolated from total RNA using the PolyAtract mRNA Isolation System (Promega). Reverse transcription was performed on 1 µg of total RNA in 7 µl of water, 13 µl of polymerization mix (using 1X buffer, 1.5 mM dNTP, 1X RNasine, Reverse transcriptase MLV from Promega) and 1 µl of random primers (Gibco) after which the mixture was incubated for 2 hours at 37°C. The PCR was performed with 1 µl of reverse transcription mix, using the high fidelity long expand thermostable polymerase ) and P2 Figure 1A ). To check the reproducibility of the inhibition and the dose-dependent effect, the four potential candidates were tested on cells at concentrations varying from 5 to 20 µg /ml. Only SAF34 and SAF61 resulted in a decrease of the PrP Sc levels that is reproducible and dose-dependent ( Figure 1B ). SAF37 failed to exhibit a classical dose-dependent inhibition curve and was toxic for the cells at 20 µg/ml whereas the inhibition observed originally with 11C6 antibody was not reproducible ( Figure 1A and B (Figure 2A and B) . The IC 50 values obtained for SAF34 and SAF61 were 1.3 ± 0.1 µg/ml (8.7
± 0.7 nM) and 0.8 ± 0.05 µg/ml (5.3 ± 0.3 nM), respectively. In addition, the toxic effects of the antibodies on N2a58/22L cells, were assessed by performing a cell numeration using the Trypan Blue dye. The results did not show any differences between the non treated control cells and the cells treated either with SAF34 or SAF61 antibodies (data not shown). SAF61 antibodies, are statistically significant from the values expected in the case of an additive effect (P <0.01, ANOVA followed by Neuman-Keuls test, see Table 2 ). Our results
Time course inhibition of PrP
showed that the inhibitory effect observed after 3 days of co-treatment was synergistic.
In order to see if we can completely cure the cells from their PrP Sc molecules, the treatment was extended to 20 days, with 1 µg/ml of SAF34 or SAF61 or both antibodies ( Figure 3A ).
After 6 ANOVA followed by Neuman-Keuls test) ( Table 2) . By contrast, 33 % of the PrP C molecules remain in cells incubated with both antibodies. From these results, it was deduced that a decrease was obtained of 10% with SAF34, around 30 % with SAF61 and about 70 % with both antibodies. We calculated that about 60 % of the PrP C levels should remain if an additive effect was observed. As only 33 % of the PrP C levels are detectable, the inhibitory effect observed after three days of treatment with both antibodies is synergistic (co-treated cells versus expected values if additive effects: P<0.001, Table 2 ). Cell viability results showed that this effect was not associated with any toxicity arising from increasing concentrations of the antibodies (data not shown). Cultures were pulse-labeled during 1 hour, then the radioactive 35 S medium was replaced by "cold" medium, followed by addition of 2 µg/ml of SAF34 or SAF61 or both antibodies during the chase period. T 1/2 of the PrP C protein was determined by densitometry analysis of the autoradiography. In the absence of antibodies, the T 1/2 for the PrP C protein was 5 hours ( Figure 5A and 5B), which is in agreement with previous studies (Caughey et al. 1989; Borchelt et al. 1990; Borchelt et al. 1992) . SAF61 antibodies diminished the T 1/2 for the PrP C protein from 5 to 3 hours and this dropped to 1.5 hours when both antibodies were present. By contrast, treatment with SAF34 antibodies did not significantly alter the T 1/2 of the PrP C protein ( 4.3 hours) ( Figure 5B ).
Anti-PrP antibodies increase the degradation of the
As a control it was identified that the antibodies did not act elsewhere other than the degradation of PrP C . To exclude the possibility that the antibodies inhibit PrP C during its biosynthesis, cells were pulse labeled in the presence of the antibodies and immediately lyzed without a chase period ( Figure 5C ). We chose a pulse of 30 min, which is the time required for exportation of the PrP protein to the membrane without degradation process. Equivalent amount of labeled PrP C was detected showing that antibodies alone or combined have no Perrier, 15th December 2003 effect on PrP C biosynthesis ( Figure 5C ). We also verified that the antibodies do not decrease the PrP mRNA expression by performing RT-PCR analysis in N2a58 cells, previously incubated with both antibodies SAF34 and SAF61 at 1 µg/ml each ( Figure 4B ). Results showed that the PrP mRNA expression level is equivalent between the control not submitted to antibody treatment and the other sample treated with SAF34 and SAF61. The PrP mRNA expression levels in the cells were not modified by the antibodies.
DISCUSSION
Because the large panel of antibodies generated by Grassi et al. (Demart et al. 1999 ) has never been tested for their potential anti-prion activity, a screening program was carried out using prion-infected cell cultures. We succeeded to find two inhibitory antibodies with different epitopes : SAF34 recognizing the flexible octarepeats region (59-89) and SAF61 which bound to the PrP amino acid residues (144-152). Comparison of SAF34 and SAF61 epitopes with those of antibodies that were previously screened for their anti-prion activity, was done by mapping them onto the PrP primary sequence (Figure 6 ). SAF34 is the only antibody directed against the N-terminal flexible region of the PrP that inhibits the PrP Sc levels in the cells. As the SAF34 epitope recognized the octarepeat region, several antibodies might be bound to the repeated motifs (Table 1) . Since E149 antibody directed against the last two octarepeat motifs antibody. Nevertheless, the duration of the treatment with D18 antibodies was 7 days compared to 6 days with SAF61. In both cases, antibody treatments were performed on prioninfected neuroblastoma cell lines, however, the N2a58/22L cells contained most likely a higher level of PrP 50 50
Sc than the ScN2a (Butler et al. 1988 ), since they are stably transfected with a murine Prnp gene (Nishida et al. 2000) . Altogether these data may suggest that SAF61 is a Experiments with normal cells treated with only one antibody showed that SAF34 and SAF61
antibodies have different mechanisms of action. The major mechanism of action of SAF61 is Perrier, 15th December 2003 to increase the clearance of the PrP C . In the presence of SAF61 the T 1/2 of PrP C was lowered to 3 hours, which provokes a strong diminution of the PrP C levels (43 % of PrP C was left at 6 days) in the cells. However it is probably not sufficient to completely eradicate PrP Sc (less than 1% of PrP Sc was left at 6 days), this would suggest the involvement of other mechanisms of action. As SAF61 antibodies recognized both PrP isoforms, it can be hypothesized that SAF61 also accelerates PrP Sc degradation. By contrast to SAF61, SAF34 alone has a minor effect on the degradation of PrP C . The T 1/2 of PrP C is nearly unchanged in presence of SAF34 (4.3 hours) that is in accordance with the almost unmodified PrP C levels (84 % of PrP C was left at 6 days) in the cells. From our results, we can conclude that SAF34 is not acting on PrP C degradation nor PrP C synthesis. In addition, the mode of action of the SAF34 antibody is not due to a direct effect on the PrP Sc isoform, since this N-terminal antibody can not interact with the cleaved PrP Sc which represents 95% of PrP Sc in the ScN2a cells (Rachidi et al. 2003) . The PrP Sc inhibition by SAF34 antibody (35 % of PrP Sc was left at 6 days) is likely due to the prevention of the formation of the molecular complexes between PrP C and PrP Sc as suggested in previous studies (Enari et al. 2001; Peretz et al. 2001 ).
The next step now is to understand how the degradation of PrP C by both antibodies occured.
One striking feature is that the epitopes of SAF61 and SAF34 antibodies correspond to the two different binding sites (BD1 and BD2) of the laminin receptor precursor (LRP) on the PrP protein (Hundt et al. 2001 ). In the co-treatment experiments, one can hypothesizes that SAF61 might hide the direct binding site between the LRP and PrP (amino acids 144-179), while SAF34, might mask the interaction at the indirect binding site (BD2) between LRP and PrP via the heparan sulfate proteoglycan (amino acids 53-93). Since PrP interactions with its receptor are disrupted, it could lead to the destabilization of the PrP protein and its accelerated Perrier, 15th December 2003 degradation. Indeed, the use of anti-LRP antibodies diminish both the PrP C as well as PrP Sc levels in prion infected cells (Leucht et al. 2003 ).
Alternatively Numerous studies have showed that the binding of an antibody to a protein can lead to conformational changes inducing the release of cofactors, as well as the inhibition or activation of enzymatic catalysis (Crumpton 1966; Rotman and Celada 1968; DjavadiOhaniance et al. 1984) . The binding of SAF61 to the PrP protein could induce conformational changes exposing amino acid residues of the PrP protein to proteases attacks.
Another question concerns the inhibition of a putative function of the PrP protein by treatment with both antibodies. This gene is not lethal as demonstrated by the generation of mice Knock-Out for the Prnp gene which exhibit a normal development and behaviour (Bueler et al. 1992) . Recently a conditional Knock-Out of the Prnp gene in adult mice was created and no effect on the animal viability was observed, suggesting that the loss of PrP function is not lethal for mice (Mallucci et al. 2002) . To the contrary, the suppression of the PrP protein in neurons protected mice from neurodegeneration caused by prions (Mallucci et al. 2003) . In this context, we may be confident that PrP C degradation caused by antibody treatment will not have a drastic effect on mice viability.
The use of antibodies represents one of the most innovative therapeutic strategy for the treatment of the neurodegenerative disorders such as Alzheimer's and Prion diseases diseases (Enari et al. 2001; Heppner et al. 2001; Peretz et al. 2001; White et al. 2003) . However, such hopes were moderated since undesirable autoimmune reactions were observed in humans during clinical trials with the Aβ1-42 vaccine for Alzheimer's disease (Birmingham et al., 2002) . In the context of prion diseases, mice treated with high dose of anti-PrP antibodies ICSM18 and ICSM35 over an extended period of 53 weeks, did not show any evidences for autoimmune reaction (White et al. 2003) . Because the treatment with SAF34 and SAF61
antibodies decrease the PrP C levels, it remains to determine whether an autoimmune reaction could appear during animal testing.
Co-treatment experiments using antibodies possessing epitopes quite far from one another in the PrP sequence maximizes the inhibitory effect. Indeed, treatment with both SAF34 and SAF61 antibodies decreased the PrP C and the PrP Sc levels synergistically suggesting that combining several antibodies in treatments would be a more efficient in vivo therapeutic strategy. Recently, antibodies that specifically target the PrPP Sc isoform were generated (Paramithiotis et al. 2003 Although serotherapy most certainly is of limited value once the clinical symptoms have manifested themselves (White et al. 2003) , the immediate use of inhibitory antibodies as preventive treatment for people that were exposed to prions, after inadvertent manipulations of the infectious agent could be envisaged. protease to protein for 1 hour at 37 ºC. PrP Sc levels were analyzed by immunobloting.
Molecular weight markers spanning 16.5-32 kDa. The star symbol means that the antibodies were not able to immunoprecipitate the PrP protein (see Table 1 ). Immunoblots are probed with SAF mix antibodies. without treatment with the antibody; (2) Cells treated with both SAF34 and SAF61 at 1 µg/ml each. Fifteen epitopes from various mAb antibodies tested for their potential anti-prion activity were mapped onto the (23-231)PrP primary sequence. Antibodies marked with an asterisk (*)
possessed an anti-prion activity and decreased the PrP Sc levels in prion infected cells or mice (Enari et al. 2001; Heppner et al. 2001; Peretz et al. 2001; White et al. 2003) , whereas the others have no inhibitory effect on PrP Sc molecules. Black boxes or striped boxes represent the epitopes of anti-PrP antibodies. Numbers correspond to amino acid position in the PrP protein.
